908 Devices, Inc. (MASS)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
$11.07+3.75%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
QuarterlyIQ Insights · MASS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 35.5% |
| Our one-year growth estimate | diamond | 30.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 5.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 1 industry peers
MASS — capital allocation — Pursuant to the terms of the Purchase
Dated 2026-05-06
Pursuant to the terms of the Purchase Agreement and as set forth in Item 1.01, the Company issued or may issue Company Shares as Option Share Payment, Stock Consideration and Earn-Out Consideration (subject to the achievement of certain milestones set forth in the Purchase Agreement) (such Company Shares, the “Transaction Shares”). The Transaction Shares were or will be issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon the exempt…
Why it matters: VipIR shipments helped drive Q2 product sales. More shipments would show that its early demand continues.
Supportive ifA later quarter reports more than 35 VipIR units shipped.
Worry ifA later quarter reports fewer VipIR shipments than Q2, or reports no new large agency orders.
Why it matters: NIRLab adds lower-cost drug testing tools and software subscriptions. Paid orders would show that agency interest is turning into sales.
Supportive ifThe company reports NIRLab product sales to U.S. agencies, with more than 30 agencies engaged at launch.
Worry ifThe company reports no NIRLab sales to U.S. agencies in its next results, or says agency interest has slowed.
Why it matters: The company raised the low end of its 2026 revenue range to $68 million. Meeting it would support its growth plan.
Supportive ifFull-year 2026 revenue is at least $68 million, within the latest $68 million to $70 million range.
Worry ifFull-year revenue falls below $68 million, or the company cuts its latest range.
Why it matters: The next report will test whether revenue growth and better margins continue. The company still reports operating losses.
Watch forQ3 revenue is above $16.1 million, and adjusted gross margin is at least 57%.
Also watch forQ3 revenue is below $16.1 million, or adjusted gross margin is below 56%.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$217 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $574 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,716 loss on $10,000 · 37.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.